Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05663853 · ClinicalTrials.gov registry record
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
A clinical trial, sponsored by LAPIX Therapeutics.
- Completed
- Registry status
- 137
- Enrollment target
NCT05663853: Completed study, sponsored by LAPIX Therapeutics.
NCT05663853 is a clinical trial that has completed, run by LAPIX Therapeutics. The registered enrollment target is 137 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05663853 has completed, sponsored by LAPIX Therapeutics.
- COMPLETED
- Registry status
- 137 participants
- Enrollment target
Study Summary
All males and females between 18-70 years of age regardless of their race and ethnicity with a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), and Relapse Remitting Multiple Sclerosis (RRMS) are invited to participate in this Observational study being conducted across four sites in the US. Since this is an observational study no medication/drug or treatment will be given to the participants. The investigator will be collecting information about the participant's MS disease, its progression, current medications, radiographic scans, and blood samples. This will help the investigator evaluate the biomarkers and new treatment options to better understand the MS disease process.
Primary Outcome
The clinical information includes the date of MS diagnosis, duration of MS, date of last clinical attack, progressive/non-progressive course of the disease, MS medications and treatment modalities, comorbidities, concomitant medications, and vaccination record.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2023-03-28 |
| Est. Completion | 2024-04-30 |
What the finished NCT05663853 record still lists
NCT05663853 is an observational study that tracks outcomes without assigning an intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05663853 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05663853 about?
NCT05663853 is a clinical study titled "An Observational Biomarker Study in Multiple Sclerosis (MS) Patients". All males and females between 18-70 years of age regardless of their race and ethnicity with a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), and Relapse Remitting Multiple Sclerosis (RRMS) are invited to participate in this Obs...
What is the current status of trial NCT05663853?
This trial is currently completed. The enrollment target is 137 participants. The study started on 2023-03-28. Estimated completion is 2024-04-30.
Who is sponsoring clinical trial NCT05663853?
This trial is sponsored by LAPIX Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI